NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the
"Company"), a leading biotech company developing
psychedelic-inspired therapies, has agreed to work with Forian Inc.
(NASDAQ: FORA), a leading provider of evidence-based support for
more comprehensive clinical and commercial decision-making.
MindMed and Forian will collaborate to develop best practices
for using real-world evidence ("RWE") information to help improve
the health and lives of psychiatric patients. Forian has deep
domain experience in RWE and outcomes studies and has developed a
variety of information products to serve the healthcare
industry.
Large, real-world health datasets drive discovery and
connections that can be missed in individual episodic health
visits. Patterns emerge when multiple visits can be seen in a
representative population.
"Our goal is to use real-world healthcare data and deep digital
phenotyping to achieve in-depth, precise and personalized
characterizations of individuals with generalized anxiety disorders
and other conditions of interest for our drug development
programs," said MindMed's Chief Medical Officer Dan Karlin, MD MA. "By fully acknowledging each
person's physiology, environment, and behavioral stressors, we
ultimately aim for integrated digital deep diagnoses to drive
precision psychiatry for drug development and clinical treatment
across our target therapeutic areas."
"Forian understands the power our real-world evidence and unique
data sets add to our healthcare and pharmaceutical partners," said
Dan Barton, Chief Executive Officer
of Forian. "We are thrilled to collaborate with MindMed to help
them deliver insights to improve the health of psychiatric
patients."
The global pandemic and its overwhelming mental health impacts
underscore the need for tailored solutions and treatments that can
be administered in a preventative rather than reactive manner.
MindMed is leveraging the recent advances in multi-omics,
real-world data and artificial intelligence to help develop precise
and personalized psychiatry tools.
About MindMed
MindMed is a clinical-stage psychedelic
medicine biotech company that seeks to discover, develop, and
deploy psychedelic-inspired medicines and therapies to address
addiction and mental illness. The Company is assembling a
compelling drug development pipeline of innovative treatments based
on psychedelic substances including psilocybin, LSD, MDMA, DMT and
an Ibogaine derivative, 18-MC. The MindMed executive team brings
extensive biopharmaceutical experience to MindMed's approach to
developing the next generation of psychedelic-inspired medicines
and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
About Forian
Forian Inc. provides a unique suite of
SaaS solutions, data management capabilities and proprietary data
and analytics to optimize and measure operational, clinical and
financial performance for customers within the traditional and
emerging life sciences, healthcare payer and provider segments, as
well as cannabis dispensaries, manufacturers, cultivators and
regulators. For more information, please visit the Company's
website at www.forian.com.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "will", "may", "should", "could",
"intend", "estimate", "plan", "anticipate", "expect", "believe",
"potential" or "continue", or the negative thereof or similar
variations. Forward-looking information in this news release
include, but are not limited to, statements regarding MindMed's
successful collaboration with Forian, the ability to use RWE for
MindMed's drug development programs, access to RWE and the
successful implementation of RWE data tools with patients. Although
the Company believes that the expectations reflected in such
forward-looking information are reasonable, such information
involves risks and uncertainties, and undue reliance should not be
placed on such information, as unknown or unpredictable factors
could have material adverse effects on future results, performance
or achievements of the Company. There are numerous risks and
uncertainties that could cause actual results and the Company's
plans and objectives to differ materially from those expressed in
the forward-looking information, including history of negative cash
flows; limited operating history; incurrence of future losses;
availability of additional capital; lack of product revenue;
compliance with laws and regulations; difficulty associated with
research and development; risks associated with clinical trials or
studies; heightened regulatory scrutiny; early stage product
development; clinical trial risks; regulatory approval processes;
novelty of the psychedelic inspired medicines industry; as well as
those risk factors discussed or referred to herein and the risks
described under the headings "Risk Factors" in the Company's
filings with the securities regulatory authorities in all provinces
and territories of Canada which
are available under the Company's profile on SEDAR at
www.sedar.com and with the U.S. Securities and Exchange Commission
on EDGAR at www.sec.gov. Should one or more of these risks or
uncertainties materialize, or should assumptions underlying the
forward-looking information prove incorrect, actual results and
future events could differ materially from those anticipated in
such information. Although the Company has attempted to identify
important risks, uncertainties and factors that could cause actual
results to differ materially, there may be others that cause
results not to be as anticipated, estimated or intended. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend and does not
assume any obligation to update this forward-looking
information.
Media Contact: mindmed@150bond.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-announces-collaboration-with-forian-to-advance-development-of-personalized-psychiatry-for-anxiety-disorders-301361284.html
SOURCE Mind Medicine (MindMed) Inc.